__

Power3 Medical Products, Inc. (OTCBB: PWRM) announced in most recent press, the collaboration with Lourdes R. Bosquez, MD, has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept®, Exelon®, and Namenda®.

These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.

__

CVS Caremark Reports Second Quarter Financial Results

CVS Caremark Corporation (NYSE: CVS), today announced revenues, operating profit, and net income for the three and six months ended June 30, 2010.

Company Revises 2010 Earnings Guidance Range

New 12-Year Contract with Aetna to Provide Significant Long-Term Benefits
Second Quarter Year-Over-Year Highlights:

- Adjusted EPS from continuing operations of $0.65, including $0.03 per diluted share of accruals in our Retail Pharmacy segment for anticipated legal settlements
- GAAP diluted EPS from continuing operations of $0.60, including $0.03 per diluted share of accruals in our Retail Pharmacy segment for anticipated legal settlements
- Net revenues of $24.0 billion
- Generic dispensing rate increased 320 basis points to 71.0% in the Pharmacy Services segment and 310 basis points to 72.7% in the Retail Pharmacy segment
- Mail choice penetration rate increased 190 basis points to 25.9%

Revenues

Net revenues for the three months ended June 30, 2010, decreased $864 million, or 3.5% to $24.0 billion, down from $24.9 billion in the prior year period.

Revenues in the Pharmacy Services segment decreased 9.0% to $11.8 billion in the three months ended June 30, 2010 over the prior year period. Adjusting the growth rate for the impact of new generics, net revenues would have decreased 3.1% in the Pharmacy Services segment. The decrease in net revenues was primarily due to the previously announced termination of a few large client contracts effective January 1, 2010 and the decrease of covered lives under our Medicare Part D program resulting from the 2010 Medicare Part D competitive bidding process. This was partially offset by new client starts effective January 1, 2010.

Revenues in the Retail Pharmacy segment increased 3.7% to $14.3 billion in the three months ended June 30, 2010 and total same store sales increased 2.1% over the prior year period. Pharmacy same store sales increased 2.9% and were positively impacted by approximately 290 basis points due to the continued growth of Maintenance Choice™. Pharmacy same store sales were negatively impacted by approximately 180 basis points due to recent generic introductions, and were negatively impacted by the comparison against last year’s H1N1 outbreak. Front store same store sales increased 0.4% in the three months ended June 30, 2010, and were negatively impacted by an earlier Easter, the inclusion of stores acquired as part of the Longs acquisition, and by the comparison against last year’s H1N1 outbreak.

The generic dispensing rate increased approximately 320 basis points to 71.0% in our Pharmacy Services segment and 310 basis points to 72.7% in our Retail Pharmacy segment, compared to the three months ended June 30, 2009.

__

Johnson Controls Announces Quarterly Dividend; Elects Brian Stief as Corporate Officer

The Directors of Johnson Controls, Inc. (NYSE: JCI) have authorized a regular quarterly cash dividend of $0.13 per common share. The dividend is payable October 4, 2010 to shareholders of record September 10, 2010.

Johnson Controls has paid consecutive dividends since 1887.

The company also announced the election of Brian Stief as a corporate officer. Stief joins Johnson Controls as Vice President, Corporate Controller, reporting to R. Bruce McDonald, Executive Vice President and Chief Financial Officer. His primary responsibilities will include global finance functions, financial planning and analysis, corporate taxation and other special projects.

Stief will also become a member of the Global Leadership Council and will work closely with the Johnson Controls business units, providing support to those senior leadership teams on strategic initiatives, including merger and acquisition opportunities. He succeeds Susan M. Kreh, who was named vice president, finance for the Power Solutions business of the company in late 2009.

“We are delighted to have Brian join our senior leadership team. He brings strong strategic and financial leadership to Johnson Controls, with over 30 years of experience in working with large, multinational publicly-traded companies,” noted McDonald. “His extensive financial background and deep understanding of the industries in which we operate, are important additions to our leadership team.”

__

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

____________________

Sign Up for our FREE Daily Stock Newsletter

____________________

DoubleInStocks would like to invite you to www.crowntradingsystems.com so you can check out the super 16 multi monitor super computer he trades on daily. If you’re looking for a multi display computer to enhance your trading then you’ll want to visit www.crowntradingsystems.com

***

 

 

Tags:

JCI |  NYSE:CVS |  NYSE:JCI |  otc:pwrm |  power3 |  Power3 Medical Products |  PWRM |  PWRM.OB